Possibilities of immunogistochemical investigation in respons prognosis to treatment and modification of treatment activities at luminal breast cancer (literature review)
Creators
- 1. SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»
- 2. ME «Dnipropetrovsk City Multidisciplinary Clinical Hospital N 4» DRC»
Description
This article is concerned with both standard (estrogen and progesterone receptors, Her2/neu and Ki67) immunohistochemical investigation in hormonal therapy tactics decision for luminal breast cancer and additional investigation of such hormonal sensibility marker as cyclin D1, Bcl-2, AIB1, Her1, p53, IGF-IR, COX-2 and its influence on modified hormonal therapy impact on tumor. It was shown that tumors expressing Her2/neu, AIB1, Her1, p53 or tumors, that have more than 30% expression of cyclin D1 are resistant to antiestrogen but sensible to aromatase inhibitors. IGF-IR and COX-2 tumors are resistant to aromatase inhibitors. Metformin usage for IGF-IR hyperexpression and oxygenase selective inhibitors for COX-2 expression promotes sensibility increase for aromatase inhibitors.
Files
4-12.pdf
Files
(315.5 kB)
Name | Size | Download all |
---|---|---|
md5:d1b60ecea6f69089133f1b68cac3dfd1
|
315.5 kB | Preview Download |
Additional details
Related works
- Is cited by
- 2307-0404 (ISSN)